SNCA and Parkinson disease: Recent clinical trials havefocused on novel strategies targeting α-synuclein and repurposingdrugs for disease modification in PD, but results have been disappointing.96 Future research directions should continue toexplore these therapeutic targets and address the challenges of theBBB in PD.